February 2019‘Nature Communications’ published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl (“Ureka”), ImmuPharma’s subsidiary.
May 2017Findings with the P140 peptide support a direct cross-talk between autophagy and certain central and peripheral neuronal diseases
November 2016Cancer compound IPP-204106 chosen to be on the cover of AACR disclosing the specific binding to nucleolin and therefore to tumour cells by the Nucants.
March 2015Special article “Resetting the autoreactive immune system with a therapeutic peptide in lupus” on autophagy
October 2013New Opportunities for Therapy of Autoimmune Diseases: published in Genetics & Epigenetics outlinung the potential in other indications
November 2012Publication of Lupuzor’s double blind phase IIb results in the Annals of the Rheumatic Diseases of the British Medical Journal
September 2012Publication in the Journal of Autoimmunity on Peptide-based approaches to treat lupus and other autoimmune diseases
December 2010Annals of the Rheumatic Diseases paper on mode of action of Lupuzor on HSC70+ antigen-presenting cells
April 2009Publication in PLoS One – Lupuzor (P140) controls Lupus by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells